Spazmol I.M./I.V./S.C. Ampul

Description

Composition and Formulation

Spazmol is available as an injectable solution with a concentration of 20 mg/ml of the active ingredient, hyoscine butylbromide. It can be administered intramuscularly (I.M.), intravenously (I.V.), or subcutaneously (S.C.).

Uses

Gastrointestinal Spasms

Spazmol is primarily prescribed for the treatment of acute gastrointestinal spasms, such as those associated with biliary and renal colic.

Diagnostic and Therapeutic Procedures

Additionally, Spazmol is utilized during diagnostic and therapeutic procedures, including gastro-duodenal endoscopy and radiology, to manage muscle spasms effectively.

Dosage and Administration

Initial Dose

For adults, the typical initial dose is 30 mg, which can be administered intramuscularly, intravenously, or subcutaneously. This dose may be repeated every 3 to 4 hours if necessary.

Maximum Dose

• Intravenous (IV): Maximum single dose is 30 mg.
• Intramuscular (IM) or Subcutaneous (SC): Maximum single dose is 60 mg.
• Daily Maximum Dose: 360 mg.

Special Considerations

• The intramuscular route is preferred for frequent injections.
• The subcutaneous route should be reserved for situations where other routes are not feasible due to the risk of severe tissue damage at the injection site.

Side Effects

Common Side Effects

• Nausea
• Vomiting
• Dizziness
• Drowsiness

Serious Side Effects

• Respiratory depression
• Severe tissue damage at the injection site (particularly with SC administration)

Precautions

Risk of Addiction

Given the potential for addiction, abuse, and misuse, Spazmol should be prescribed only when alternative treatment options have proven ineffective.

Monitoring

Patients should be closely monitored for respiratory depression, especially at the beginning of treatment and with each dose increase.

Drug Interactions

Anticholinergic Medications

The anticholinergic effects of medications such as tri- and tetracyclic antidepressants, antihistamines, antipsychotics, quinidine, amantadine, disopyramide, and other anticholinergics (e.g., tiotropium, ipratropium, atropine-like compounds) can be intensified by Spazmol.

Hypnotics and Anti-Epileptics

Certain hypnotics and anti-epileptics, including glutethimide, phenobarbital, phenytoin, and carbamazepine, may interact with Spazmol. Additionally, substances like rifampicin and potentially hepatotoxic substances, as well as alcohol abuse, should be avoided.

Food and Drink Interactions

• Alcohol: Consuming alcohol while taking Spazmol can increase the risk of side effects such as drowsiness and dizziness.

Monitoring and Precautions

Consult a healthcare provider before starting Spazmol, particularly if you are taking other medications, to manage and monitor potential drug interactions and ensure safety.

Contraindications

Allergic Reactions

• Hypersensitivity: Spazmol should not be used in patients with known hypersensitivity to hyoscine butylbromide or any other component of the product.

Medical Conditions

• Myasthenia Gravis
• Glaucoma (especially untreated narrow-angle glaucoma)
• Megacolon
• Mechanical Stenosis of the gastrointestinal tract
• Paralytic or Obstructive Ileus
• Tachyarrhythmia
• Prostatic Hypertrophy
• Achalasia

Special Considerations

• Anticoagulant Therapy: Spazmol should not be administered intramuscularly to patients on anticoagulant therapy due to the risk of bleeding.

Storage Conditions

Temperature

Store at room temperature, away from direct sunlight, heat, and moisture.

Location

Do not store in the bathroom. Keep all medications out of reach of children.

Proper storage ensures the medication remains effective and safe to use.

Shelf Life

The shelf life of Spazmol I.M./I.V./S.C. Ampul is typically five years from the date of manufacture. Adhering to storage guidelines is crucial to maintaining its efficacy.

Pregnancy and Breastfeeding Precautions

Pregnancy

• Risk Assessment: The use of Spazmol during pregnancy should be considered only if the potential benefits outweigh the risks. Consultation with a healthcare provider is essential.
• Potential Risks: Limited data on the safety of Spazmol during pregnancy suggests it should be used with caution and under medical supervision.

Breastfeeding

• Breast Milk Transfer: Spazmol can pass into breast milk and may affect the nursing infant.
• Infant Effects: Even small doses can induce sleepiness and altered brain function in infants.
• Recommendation: It is generally advised to avoid using Spazmol while breastfeeding. If necessary, breastfeeding should be discontinued to prevent potential harm to the infant.

Always consult a healthcare provider before using Spazmol during pregnancy or breastfeeding to ensure the safety of both mother and baby.

Mechanism of Action

How It Works

Spazmol contains hyoscine butylbromide, an antispasmodic and anticholinergic agent.

• Muscarinic M3 Receptors: Hyoscine butylbromide binds to muscarinic M3 receptors in the gastrointestinal tract, preventing acetylcholine from binding and activating these receptors, which would normally cause smooth muscle contraction.
• Inhibition of Contraction: By inhibiting smooth muscle contraction, Spazmol reduces spasms and related pain during abdominal cramping.
• Peripheral Action: As a quaternary ammonium compound, hyoscine butylbromide primarily exerts its effects peripherally without significant central nervous system side effects.

Effects

• Spasmolytic Action: Spazmol exerts a spasmolytic effect on the smooth muscle of the gastrointestinal, biliary, and urinary tracts.
• Anticholinergic Effects: The peripheral anticholinergic effects result in the relaxation of smooth muscles, reducing spasms and associated discomfort.

Table of Information

In conclusion, Spazmol I.M./I.V./S.C. Ampul is an effective medication for managing muscle spasms, especially in the gastrointestinal tract. Adherence to prescribed dosages, awareness of side effects, and consultation with healthcare providers for contraindications and interactions are essential for safe and effective use